The epidermal growth factor receptor (EGFR)‐TKI osimertinib is a preferred therapy for patients with non‐small cell lung cancer (NSCLC) driven by activating mutations in EGFR, unfortunately responses are heterogeneous. Here, EGFR is linked to non-small cell lung carcinoma.